119 related articles for article (PubMed ID: 33952488)
1. Switching from Intravenous to Oral Tacrolimus Reduces its Blood Concentration in Paediatric Cancer Patients.
Ujiie H; Nihei S; Nishiya N; Goto S; Asakura Y; Miura S; Hirai D; Endo M; Oyake T; Ito S; Chiba T; Kudo K
Anticancer Res; 2021 May; 41(5):2591-2596. PubMed ID: 33952488
[TBL] [Abstract][Full Text] [Related]
2. Clinical Factors Affecting the Dose Conversion Ratio from Intravenous to Oral Tacrolimus Formulation among Pediatric Hematopoietic Stem Cell Transplantation Recipients.
Kanamitsu K; Yorifuji T; Ishida H; Fujiwara K; Washio K; Shimada A; Tsukahara H
Ther Drug Monit; 2020 Dec; 42(6):803-810. PubMed ID: 32732549
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus blood concentration increase depends on administration route when combined with voriconazole in pediatric stem cell transplant recipients.
Utano T; Kato M; Osumi T; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Matsumoto K; Yamatani A
Pediatr Transplant; 2020 Feb; 24(1):e13619. PubMed ID: 31820535
[TBL] [Abstract][Full Text] [Related]
4. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.
Mimura A; Yamaori S; Ikemura N; Katsuyama Y; Matsuzawa N; Ohmori S
J Clin Pharm Ther; 2019 Aug; 44(4):565-571. PubMed ID: 30950099
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
Suetsugu K; Ikesue H; Miyamoto T; Shiratsuchi M; Yamamoto-Taguchi N; Tsuchiya Y; Matsukawa K; Uchida M; Watanabe H; Akashi K; Masuda S
Int J Hematol; 2017 Mar; 105(3):361-368. PubMed ID: 27822915
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
Wallemacq PE; Furlan V; Möller A; Schäfer A; Stadler P; Firdaous I; Taburet AM; Reding R; Clement De Clety S; De Ville De Goyet J; Sokal E; Lykavieris L; Van Leeuw V; Bernard O; Otte JB; Undre NA
Eur J Drug Metab Pharmacokinet; 1998; 23(3):367-70. PubMed ID: 9842978
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.
Kolb M; Offer K; Jin Z; Kahn J; Bhatia M; Kung AL; Garvin JH; George D; Satwani P
Biol Blood Marrow Transplant; 2016 May; 22(5):957-61. PubMed ID: 26880117
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus clearance is age-dependent within the pediatric population.
Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
[TBL] [Abstract][Full Text] [Related]
10. Intrapatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy.
Sagou K; Fukushima N; Ukai S; Goto M; Ozeki K; Kohno A
Int J Hematol; 2021 Jan; 113(1):63-72. PubMed ID: 32876853
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
[TBL] [Abstract][Full Text] [Related]
12. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
[TBL] [Abstract][Full Text] [Related]
13. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
14. Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
Bacopoulos AJ; Ho L; Yang A; Ng P; Dara C; Loach D; Deotare U; Michelis FV; Viswabandya A; Kim DD; Lipton JH; Messner HA; Thyagu S
J Oncol Pharm Pract; 2021 Jan; 27(1):33-39. PubMed ID: 32183586
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients.
Nasiri-Toosi Z; Dashti-Khavidaki S; Nasiri-Toosi M; Khalili H; Jafarian A; Irajian H; Abdollahi A; Sadrai S
Exp Clin Transplant; 2012 Dec; 10(6):586-91. PubMed ID: 22770208
[TBL] [Abstract][Full Text] [Related]
16. Conversion ratio of tacrolimus switching from intravenous infusion to oral administration after lung transplantation.
Yang C; Xi Y; Chen WY; Sang L; Liu DD; Zhang R; Chen SB; Zhang J; Pan JY; Xv YH; Nong LB; Li YM; Liu XQ
J Thorac Dis; 2020 Aug; 12(8):4292-4298. PubMed ID: 32944341
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Administration of Tacrolimus Stabilizes Control of Blood Concentration Regardless of CYP3A5 Polymorphism in Living Donor Liver Transplantation: Comparison of Intravenous Infusion and Oral Administration in Early Postoperative Period.
Kato H; Usui M; Muraki Y; Okuda M; Nakatani K; Hayasaki A; Ito T; Iizawa Y; Murata Y; Tanemura A; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Isaji S
Transplant Proc; 2018 Nov; 50(9):2684-2689. PubMed ID: 30401377
[TBL] [Abstract][Full Text] [Related]
18. Use of sublingual tacrolimus in lung transplant recipients.
Watkins KD; Boettger RF; Hanger KM; Leard LE; Golden JA; Hoopes CW; Singer JP
J Heart Lung Transplant; 2012 Feb; 31(2):127-32. PubMed ID: 22177691
[TBL] [Abstract][Full Text] [Related]
19. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation.
Butts AR; Brown VT; McBride LD; Bolaños-Meade J; Bryk AW
J Oncol Pharm Pract; 2016 Apr; 22(2):275-83. PubMed ID: 25802301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
